PE HUB Healthcare Wire Highlights, 6.6.19


Pamplona Capital, private equity, healthcare,
Sarah Pringle of Buyouts. Photo by Robert Daniel, Buyouts.

As Goldman writes big check in eye care, others steer clear of retail health

It’s Thursday, and more than one private equity fund has taken a victory lap this week in healthcare. Wowza.

To start, the largest-ever sponsor transaction in the vision-care space kicked off the week, with Goldman’s PE arm striking a $2.7 billion deal for Altas and CDPQ’s MyEyDr. Read my story for more info.

Other firms making bold moves were Genstar, preempting the process for Advarra through an about $1.3 billion deal for the Linden– and Northlane-backed provider of compliance-type services for clinical research. Linden is poised to generate a handsome return, I am told.

Finally, Advent — just weeks after its bet in home care — put a quick stop to the process for Spectrum Equity’s Definitive Healthcare. The firm invested in the healthcare data provider in a deal valued around $1.7 billion, sources told me.

In notable exits, Bain Capital and Diamond Capital this morning disclosed an agreement to sell Beacon Health Options to Anthem. What are the metrics on the deal? Shoot me a note at [email protected].

In the midst of the flurry of activity … I also got the chance to swing by the Jefferies Healthcare Conference at the Grand Hyatt in NYC, where a June 4 panel of PE executives discussed market dynamics.

Why some large-cap sponsors are avoiding retail health

While we may have seen one of 2019’s biggest bets in retail health this week, some large-cap sponsors are opting out of the segment, which is often considered the most recession resilient.

CONTINUE READING 

SUBSCRIBE to get the  Healthcare Wire in your inbox every Thursday morning. It’s free!

 

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.